Cargando…

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis

BACKGROUND: Infliximab is a chimeric monoclonal antibody against tumour necrosis factor‐alpha for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Recently, a subcutaneous formulation of CT‐P13, an infliximab biosimilar, was approved for clinical use. AIMS: To characterise CT‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanzel, Jurij, Bukkems, Laura H., Gecse, Krisztina B., D’Haens, Geert R., Mathôt, Ron A. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Infliximab Biosimilar in IBD
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292975/ https://www.ncbi.nlm.nih.gov/pubmed/34559426 http://dx.doi.org/10.1111/apt.16609

Ejemplares similares

The effectiveness and safety of infliximab compared with biosimilar CT‐P13, in 3112 patients with ulcerative colitis
por: Meyer, Antoine, et al.
Publicado: (2019)

What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?
por: Card, Timothy, et al.
Publicado: (2018)

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
por: Lichtenstein, Gary R, et al.
Publicado: (2018)

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis
por: Berends, Sophie E., et al.
Publicado: (2018)

Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study
por: Hanzel, Jurij, et al.
Publicado: (2021)

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy
por: Colombel, J.‐F., et al.
Publicado: (2016)

Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients
por: Berends, Sophie E., et al.
Publicado: (2019)

PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
por: Mahadevan, Uma, et al.
Publicado: (2018)

Opportunistic Knocks: A Gardener with Ulcerative Colitis and New Pulmonary Nodules
por: Canakis, Andrew, et al.
Publicado: (2023)

Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index
por: Bots, Steven, et al.
Publicado: (2021)

A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease
por: Piester, Travis, et al.
Publicado: (2018)

Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient–Physician Visits
por: Rubin, David T., et al.
Publicado: (2017)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

A Reliability Study: Strong Inter-Observer Agreement of an Expert Panel for Intestinal Ultrasound in Ulcerative Colitis
por: De Voogd, Floris, et al.
Publicado: (2021)

IBD LIVE Case Series–Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment?
por: Le, Peter N., et al.
Publicado: (2015)

Ulcerative Colitis: Shifting Sands
por: D’Haens, Geert R. A. M., et al.
Publicado: (2019)

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
por: Fasanmade, Adedigbo A., et al.
Publicado: (2009)

High prevalence of ulcerative appendicitis in patients with ulcerative colitis
por: Heuthorst, Lianne, et al.
Publicado: (2021)

Validation Study of Novel Point-of-Care Tests for Infliximab, Adalimumab and C-Reactive Protein in Capillary Blood and Calprotectin in Faeces in an Ambulatory Inflammatory Bowel Disease Care Setting
por: Volkers, Adriaan, et al.
Publicado: (2023)

Wound healing of metastatic perineal Crohn’s disease using hyperbaric oxygen therapy: A case series
por: Lansdorp, Corine A, et al.
Publicado: (2020)

GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2017)

SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2021)

AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008)

Intestinal ultrasound detects an increased diameter and submucosal layer thickness in the appendix of patients with ulcerative colitis compared to healthy controls – a prospective cohort study
por: Reijntjes, Maud A., et al.
Publicado: (2022)

Predictive factors of response to infliximab therapy in Brazilian inflammatory bowel disease patients
por: Martins, Camilla de Almeida, et al.
Publicado: (2023)

Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation
por: Berends, Sophie E., et al.
Publicado: (2019)

The knowledge and skills needed to perform intestinal ultrasound for inflammatory bowel diseases—an international Delphi consensus survey
por: Madsen, Gorm Roager, et al.
Publicado: (2022)

Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease
por: de Bruyn, Jessica R., et al.
Publicado: (2018)

Prognostic Value of Colonic Tissue and Blood Eosinophils in Ulcerative Colitis
por: Haasnoot, Maria L, et al.
Publicado: (2022)

Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction
por: D’Haens, Geert, et al.
Publicado: (2023)

Mendelian Disease Associations Reveal Novel Insights into Inflammatory Bowel Disease
por: Han, Lichy, et al.
Publicado: (2018)

The Association Between Sustained Poor Quality of Life and Future Opioid Use in Inflammatory Bowel Disease
por: Anderson, Alyce, et al.
Publicado: (2018)

Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population‐based cohort study
por: Eriksson, Carl, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u03c3dopgl4f9m8sa7b1a5i74m